Personalized Cell Therapy Market to Make Great Impact in Near Future

Individualized treatment for various diseases such as cancer and autoimmune diseases by injecting living cells into a patient’s body is known as personalized cell therapy. It has various applications such as platelet transfusions, bone marrow transplantation, whole blood transfusions, packed red cell transfusions, and organ transplantation. It is used to treat various chronic conditions such as Parkinson’s disease and amyotrophic lateral sclerosis (neurological diseases), spinal cord injuries, diabetes, and cancer.

Personalized cell therapy refers to patient-specific therapies used to treat a variety of ailments. The medicine created by this therapy targets patients who fit the precise disease physiopathology and/or patient characteristics, and is based on the genomic profile, disease prevalence/severity, and tailored cell therapy. A high unmet need condition such as cancer, autoimmune disease, cardiovascular, neurologic, and inflammatory disease is the major target of tailored cell therapy. Platelet transfusions, packed red cell transfusions, bone marrow transplants, and organ transplants can all benefit from personalised cell therapy.

Personalized Cell Therapy Market Dynamics

Personalized cell therapy aids in accurate diagnosis of the disease and active monitoring of the treatment response, and disease progression. This allows for early detection of diseases at molecular level and allows physician to prepare treatment regime for the specific patient requirement. This helps the patient to recover at a significant pace and also helps avoid any major side effects, as individualized cell therapy is based on patient’s genomics.

Introduction of innovative personalized cell therapy and large number of cell therapies in pipeline by key players is expected to boost the market growth over the forecast period. For instance, in August 2017, the University of Pennsylvania and Children’s Hospital of Philadelphia (CHOP) received the U.S. Food and Drug Administration (FDA) approval for its newly developed personalized cellular therapy indicated for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.